![Senthil Sundaram](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Senthil Sundaram
Keine laufenden Positionen mehr
Profil
Senthil Sundaram held several positions in the pharmaceutical industry, including Chief Executive Officer & Director at Terns Pharmaceuticals, Inc., Vice President & Head-Business Development at Intercept Pharmaceuticals, Inc., and CFO & Principal Accounting Officer at Nightstar Therapeutics Ltd. He also served as an Independent Director at Sio Gene Therapies, Inc. and Social Capital Suvretta Holdings Corp.
I.
Sundaram received his undergraduate degree from Brown University.
Ehemalige bekannte Positionen von Senthil Sundaram
| Unternehmen | Position | Ende |
|---|---|---|
| TERNS PHARMACEUTICALS, INC. | Vorstandsvorsitzender | 03.08.2023 |
| SIO GENE THERAPIES INC. | Direktor/Vorstandsmitglied | 05.04.2023 |
NightstaRx Ltd.
 NightstaRx Ltd. Medical/Nursing ServicesHealth Services development of therapies for retinal dystrophies | Direktor/Vorstandsmitglied | 07.06.2019 |
| NIGHTSTAR THERAPEUTICS PLC | Finanzdirektor/CFO | 07.06.2019 |
| INTERCEPT PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.03.2017 |
Ausbildung von Senthil Sundaram
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
55
Beziehungen ersten Grades
7
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
Intercept Pharmaceuticals, Inc.
 Intercept Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for the treatment of chronic fibrotic and metabolic diseases | Health Technology |
Brown University
 Brown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
NightstaRx Ltd.
NightstaRx Ltd. Medical/Nursing ServicesHealth Services development of therapies for retinal dystrophies | Health Services |
Sio Gene Therapies, Inc.
 Sio Gene Therapies, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops gene therapies to treat neurodegenerative diseases | Health Technology |
Nightstar Therapeutics Ltd.
 Nightstar Therapeutics Ltd. BiotechnologyHealth Technology Operates as a gene therapy company that develops novel treatments for patients suffering from inherited retinal diseases | Health Technology |
Terns Pharmaceuticals, Inc.
 Terns Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops small-molecule product candidates to address serious diseases including oncology and obesity | Health Technology |
Social Capital Suvretta Holdings Corp. I
 Social Capital Suvretta Holdings Corp. I Financial ConglomeratesFinance Operates as blank check company | Finance |
